CAPLIPOINT Caplin Point Laboratories Q4 FY26 results (Jan–Mar 2026) and concall
Caplin Point Laboratories Limited reported a strong Q4 and FY26, with revenue doubling and liquid assets tripling. The company highlighted significant investments in new injectable facilities, digitalization, and R&D, alongside successful expansion in the US and LATAM markets. Despite a temporary increase in receivables due to a large tender, management expressed confidence in its anti-fragile business model, robust cash generation, and strategic growth initiatives, including a target to double US own label revenue in FY27.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 19.5%, net profit up 19.3% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 483 | 493 | 502 | 510 | 534 +11% | 543 +10% | 600 +20% |
| EBITDA | 165 | 162 | 168 | 178 | 189 +15% | 190 +17% | 204 +21% |
| Net profit | 131 | 140 | 145 | 151 | 160 +22% | 166 +19% | 173 +19% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
